These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 31135562)

  • 1. A diagnostic 'C' saw: the ups and downs of C1q testing.
    Gebel HM; Bray RA
    Curr Opin Organ Transplant; 2019 Aug; 24(4):402-410. PubMed ID: 31135562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. C1q Binding Activity of De Novo Donor-specific HLA Antibodies in Renal Transplant Recipients With and Without Antibody-mediated Rejection.
    Yell M; Muth BL; Kaufman DB; Djamali A; Ellis TM
    Transplantation; 2015 Jun; 99(6):1151-5. PubMed ID: 25839705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical relevance of pretransplant anti-HLA donor-specific antibodies: does C1q-fixation matter?
    Crespo M; Torio A; Mas V; Redondo D; Pérez-Sáez MJ; Mir M; Faura A; Guerra R; Montes-Ares O; Checa MD; Pascual J
    Transpl Immunol; 2013 Dec; 29(1-4):28-33. PubMed ID: 23907088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of C1q fixing donor-specific antibodies on renal transplant outcome.
    Baranwal AK; Goswami S; Agarwal SK; Kaur G; Mehra NK
    Scand J Immunol; 2021 Jul; 94(1):e13048. PubMed ID: 33914934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complement-fixing antibodies against denatured HLA and MICA antigens are associated with antibody mediated rejection.
    Cai J; Terasaki PI; Zhu D; Lachmann N; Schönemann C; Everly MJ; Qing X
    Exp Mol Pathol; 2016 Feb; 100(1):45-50. PubMed ID: 26615783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preformed C1q-binding Donor-specific Anti-HLA Antibodies and Graft Function After Kidney Transplantation.
    Okabe Y; Noguchi H; Miyamoto K; Kaku K; Tsuchimoto A; Masutani K; Nakamura M
    Transplant Proc; 2018 Dec; 50(10):3460-3466. PubMed ID: 30577221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determining donor-specific antibody C1q-binding ability improves the prediction of antibody-mediated rejection in human leucocyte antigen-incompatible kidney transplantation.
    Malheiro J; Tafulo S; Dias L; Martins S; Fonseca I; Beirão I; Castro-Henriques A; Cabrita A
    Transpl Int; 2017 Apr; 30(4):347-359. PubMed ID: 27717025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical impact of complement (C1q, C3d) binding De Novo donor-specific HLA antibody in kidney transplant recipients.
    Lee H; Han E; Choi AR; Ban TH; Chung BH; Yang CW; Choi YJ; Oh EJ
    PLoS One; 2018; 13(11):e0207434. PubMed ID: 30427941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Value of the Persistence of C1q-Binding Anti-HLA Antibodies in Acute Antibody-Mediated Rejection in Kidney Transplantation.
    Bailly E; Anglicheau D; Blancho G; Gatault P; Vuiblet V; Chatelet V; Morelon E; Malvezzi P; Parissiadis A; Tourret J; Guidicelli G; Sayegh J; Mousson C; Grimbert P; Top I; Le Quintrec M; Purgus R; Westeel PF; Proust B; Chabot V; Lebranchu Y; Dehaut F; Büchler M
    Transplantation; 2018 Apr; 102(4):688-698. PubMed ID: 29135832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of Pretransplant Complement-fixing Donor-specific Antibodies Identified by C1q Assay in Kidney Transplantation.
    Thammanichanond D; Wiwattanathum P; Mongkolsuk T; Kantachuvesiri S; Worawichawong S; Vallipakorn SA; Kitpoka P
    Transplant Proc; 2016 Apr; 48(3):756-60. PubMed ID: 27234729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of complement-fixing donor-specific antibodies identified by a C1q assay after heart transplantation.
    Farrero Torres M; Pando MJ; Luo C; Luikart H; Valantine H; Khush K
    Clin Transplant; 2017 Nov; 31(11):. PubMed ID: 28940521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complement-binding anti-HLA antibodies are independent predictors of response to treatment in kidney recipients with antibody-mediated rejection.
    Viglietti D; Bouatou Y; Kheav VD; Aubert O; Suberbielle-Boissel C; Glotz D; Legendre C; Taupin JL; Zeevi A; Loupy A; Lefaucheur C
    Kidney Int; 2018 Oct; 94(4):773-787. PubMed ID: 29801667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Failure to remove de novo donor-specific HLA antibodies is influenced by antibody properties and identifies kidney recipients with late antibody-mediated rejection destined to graft loss - a retrospective study.
    Cioni M; Nocera A; Tagliamacco A; Basso S; Innocente A; Fontana I; Magnasco A; Trivelli A; Klersy C; Gurrado A; Ramondetta M; Boghen S; Catenacci L; Verrina E; Garibotto G; Ghiggeri GM; Cardillo M; Ginevri F; Comoli P
    Transpl Int; 2019 Jan; 32(1):38-48. PubMed ID: 30076765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Donor-specific antibody characteristics, including persistence and complement-binding capacity, increase risk for chronic lung allograft dysfunction.
    Iasella CJ; Ensor CR; Marrari M; Mangiola M; Xu Q; Nolley E; Moore CA; Morrell MR; Pilewski JM; Sanchez PG; McDyer JF; Zeevi A
    J Heart Lung Transplant; 2020 Dec; 39(12):1417-1425. PubMed ID: 32981841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Post-transplant development of C1q-positive HLA antibodies and kidney graft survival.
    Piazza A; Poggi E; Ozzella G; Adorno D
    Clin Transpl; 2013; ():367-75. PubMed ID: 25095531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of complement binding assays to assess the efficacy of antibody mediated rejection therapy and prediction of graft survival in kidney transplantation.
    Ramon DS; Huang Y; Zhao L; Rendulic T; Park JM; Sung RS; Samaniego M
    Hum Immunol; 2017 Feb; 78(2):57-63. PubMed ID: 27894836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of Circulating Complement-Fixing Donor-Specific Antibodies Identified by the C1q Assay and Presence of C4d in Endomyocardial Biopsy Specimens.
    Frank R; Lal P; Kearns J; Molina MR; Wald JW; Goldberg LR; Kamoun M
    Am J Clin Pathol; 2016 Jan; 145(1):62-8. PubMed ID: 26712872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complement-Activating Anti-HLA Antibodies in Kidney Transplantation: Allograft Gene Expression Profiling and Response to Treatment.
    Lefaucheur C; Viglietti D; Hidalgo LG; Ratner LE; Bagnasco SM; Batal I; Aubert O; Orandi BJ; Oppenheimer F; Bestard O; Rigotti P; Reisaeter AV; Kamar N; Lebranchu Y; Duong Van Huyen JP; Bruneval P; Glotz D; Legendre C; Empana JP; Jouven X; Segev DL; Montgomery RA; Zeevi A; Halloran PF; Loupy A
    J Am Soc Nephrol; 2018 Feb; 29(2):620-635. PubMed ID: 29042454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of C1q-binding anti-HLA antibodies as a predictor of lung allograft outcome.
    Brugière O; Roux A; Le Pavec J; Sroussi D; Parquin F; Pradère P; Dupin C; Bunel V; Mourin G; Jebrak G; Dauriat G; Castier Y; Mordant P; Lortat-Jacob B; Jean-Baptiste S; Mal H; Suberbielle C; Gautreau C; Caillat-Zucman S; Cazes A; Thabut G; Taupin JL
    Eur Respir J; 2018 Aug; 52(2):. PubMed ID: 29976654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Donor-specific HLA antibodies: evaluating the risk for graft loss in renal transplant recipients with isotype switch from complement fixing IgG1/IgG3 to noncomplement fixing IgG2/IgG4 anti-HLA alloantibodies.
    Arnold ML; Ntokou IS; Doxiadis II; Spriewald BM; Boletis JN; Iniotaki AG
    Transpl Int; 2014 Mar; 27(3):253-61. PubMed ID: 24118579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.